ArticleACS applied nano materials2025
Plasmonic Nanoceria: A Plasmon-Enhanced Nanohybrid for Rapid and Sensitive Detection of Ebola Glycoprotein.
Article in ACS applied nano materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interfacial Redox Recycling Nanocatalysts with Ultrahigh Peroxidase Activity for Colorimetric Sensing Applications.ACS applied nano materials · 2026Article
- Plasmonic ELISA for Biomarker Detection: A Review of Mechanisms, Functionalization Strategies, and Emerging Modalities.ACS applied bio materials · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Frequent Ebola outbreaks on an unprecedented scale in resource-limited countries have resulted in higher fatality rates for the human population. Thereby, the development of a biosensor platform that can be used for point-of-care (PoC) tests and simultaneously features high sensitivity and selectivity is urgently needed. Herein, an approach for formulating multifunctional nanocomposite materials, plasmonic nanoceria (PNC), is presented, and its application as a sensing platform for the detection of Ebolavirus glycoprotein (EGP) of the Zaire strain is demonstrated. The synthetic strategy for PNC allows optical tunability, a unique approach to amplify detection sensitivity introduced by encapsulating gold nanoparticles (GNPs) within the polymeric coatings of cerium oxide nanoparticles (NC). Through altered optical characteristics of GNPs within the PNC, which include changes in localized surface plasmon resonance (SPR), higher detection sensitivity is achieved. Following surface conjugation of PNC with EGP-specific antibodies, a quantitative detection limit as low as 10 pM (0.7 ng/mL) is achieved. Moreover, antibody-functionalized PNC exhibits faster, reproducible, and highly sensitive colorimetric readouts, with a detectable SPR shift in the presence of EGP. Importantly, the limit of detection of EGP evaluated in complex sample matrices was comparable to as attained in a simple buffer. Specificity studies suggest that the developed PNC nanoplatform allows for both detection and differentiation between Ebola virus subtypes. Overall, the formulated PNC holds great potential for the rapid, ultrasensitive, and on-site detection of biomarker EGP of the Zaire strain and can be customized for the detection of other pathogens.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.